4C9 Stock Overview
CVS Group plc, together with its subsidiaries, engages in veterinary, pet crematoria, online pharmacy, and retail businesses.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
CVS Group plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£10.90 |
| 52 Week High | UK£25.40 |
| 52 Week Low | UK£10.50 |
| Beta | 0.95 |
| 1 Month Change | -6.03% |
| 3 Month Change | -42.63% |
| 1 Year Change | -53.81% |
| 3 Year Change | -52.57% |
| 5 Year Change | 52.34% |
| Change since IPO | 233.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4C9 | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 0.9% | 5.4% | 1.7% |
| 1Y | -53.8% | 0.6% | 2.3% |
Return vs Industry: 4C9 underperformed the German Healthcare industry which returned 1.9% over the past year.
Return vs Market: 4C9 underperformed the German Market which returned 2.2% over the past year.
Price Volatility
| 4C9 volatility | |
|---|---|
| 4C9 Average Weekly Movement | 8.4% |
| Healthcare Industry Average Movement | 6.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4C9's share price has been volatile over the past 3 months.
Volatility Over Time: 4C9's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 9,100 | Richard William Fairman | www.cvsukltd.co.uk |
CVS Group plc, together with its subsidiaries, engages in veterinary, pet crematoria, online pharmacy, and retail businesses. The company operates through four segments: Veterinary Practices, Laboratories, Crematoria, and Online Retail Business. It operates in animal veterinary practices and complementary veterinary diagnostic businesses.
CVS Group plc Fundamentals Summary
| 4C9 fundamental statistics | |
|---|---|
| Market cap | €802.72m |
| Earnings (TTM) | €41.23m |
| Revenue (TTM) | €747.59m |
19.5x
P/E Ratio1.1x
P/S RatioIs 4C9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4C9 income statement (TTM) | |
|---|---|
| Revenue | UK£641.90m |
| Cost of Revenue | UK£365.20m |
| Gross Profit | UK£276.70m |
| Other Expenses | UK£241.30m |
| Earnings | UK£35.40m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 26, 2024
| Earnings per share (EPS) | 0.49 |
| Gross Margin | 43.11% |
| Net Profit Margin | 5.51% |
| Debt/Equity Ratio | 59.6% |
How did 4C9 perform over the long term?
See historical performance and comparison